SLC5A1: Sodium/glucose cotransporter 1
Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose or D-galactose at the plasma membrane, with a Na(+) to sugar coupling ratio of 2:1.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on SLC5A1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| Sotagliflozin | Approved | Lexicon Pharmaceuticals | Small molecule | InhibitorSodium/glucose cotransporter 1 inhibitor | 19 |
| Licogliflozin | Phase 2 | Novartis Pharmaceuticals | Small molecule | InhibitorSodium/glucose cotransporter 1 inhibitor | 0 |
- Glucose-galactose malabsorption0.82
- Type 2 diabetes mellitus0.54
- Heart failure0.52
- Type 1 diabetes mellitus0.51
- Chronic kidney disease0.47
- Diabetes mellitus0.39
- Abnormal glucose tolerance0.37
- Nasopharyngeal neoplasm0.37
- Diabetic kidney disease0.28
- Hypertrophic cardiomyopathy0.27
- Renal glycosuria0.27
- Cardiovascular disorder0.26
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4979, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P13866, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets